Plastic Bottles Transformed into Parkinson's Drug by Engineered Bacteria

Every year, the world produces around 50 million tonnes of PET plastic — the stuff your water bottles, food trays, and soft drink containers are made from. Most of it ends up in landfill, incineration, or worse, polluting oceans and landscapes. But a team at the University of Edinburgh has found a way to give that waste a remarkable second life: as medicine for one of the world's most common neurological diseases.

In a study published this week in Nature Sustainability, Professor Stephen Wallace and his colleagues describe how they engineered common E. coli bacteria to convert PET plastic waste into L-DOPA (levodopa), the primary drug used to manage the symptoms of Parkinson's disease. It is the first time a biological process has been used to turn plastic pollution into a treatment for neurological disease.

What is L-DOPA, and why does it matter?

Parkinson's disease affects millions of people worldwide, causing tremors, stiffness, and difficulty with movement. The condition results from the loss of brain cells that produce dopamine, a chemical messenger essential for controlling movement. L-DOPA is the gold-standard treatment — a precursor molecule that the body converts into dopamine to replace what has been lost.

Global production of L-DOPA currently stands at around 250 tonnes per year, according to the research paper, with demand expected to rise as Parkinson's prevalence grows. Until now, commercial production has relied on chemical and enzyme-based methods using fossil fuel-derived raw materials — an energy-intensive process dependent on finite resources.

How it works

The Edinburgh team's approach is elegantly simple in concept, even if the biology behind it is cutting-edge. First, PET plastic is broken down into its chemical building blocks, specifically terephthalic acid. Then, engineered E. coli bacteria perform a series of biological reactions that transform those molecules into L-DOPA.

The researchers had to overcome two key technical challenges: getting the bacteria to efficiently absorb the plastic-derived material, and preventing a chemical intermediate from inhibiting the production process. Their solution involved splitting the work across two specially designed bacterial strains that operate in tandem.

The resulting bioprocess achieved L-DOPA concentrations of 5.0 grams per litre — a significant yield — and the team successfully isolated the drug at what they call "preparative scale" from both industrial PET waste and, remarkably, a single post-consumer plastic bottle.

As an added environmental bonus, the team used a microalgae species, Chlamydomonas reinhardtii, to capture CO₂ released during part of the conversion process.

Beyond the lab

The process operates under mild, water-based conditions, making it far gentler on the environment than traditional pharmaceutical manufacturing. But is this ready for your local pharmacy? Not yet.

The researchers are clear that the technology is still at an early stage. The next phase will focus on scaling up, optimising efficiency, and assessing the economic and environmental performance needed for industrial application.

The research was carried out at the University's new £14 million Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop), funded by the Engineering and Physical Sciences Research Council. The team believes the same approach could eventually produce flavourings, fragrances, cosmetics, and industrial chemicals from plastic waste.

"This feels like just the beginning," said Professor Wallace. "If we can create medicines for neurological disease from a waste plastic bottle, it's exciting to imagine what else this technology could achieve. Plastic waste is often seen as an environmental problem, but it also represents a vast, untapped source of carbon."

The bigger picture

Turning a pollutant into something precious is a powerful idea. In a world struggling with both a plastic waste crisis and rising demand for neurological medications, a technology that addresses both deserves attention — even at this early stage. The Edinburgh team is careful not to oversell it. This is lab-scale science, and the road to industrial production is long.

But the proof of concept is real, peer-reviewed, and published in one of the world's leading sustainability journals. And that single plastic bottle, reimagined as Parkinson's medication, is a potent symbol of what engineering biology might achieve.